CHARACTERISTICS AND TREATMENT OUTCOMES OF ACUTE MYELOID LEUKEMIA IN INFANTS AT THE BLOOD TRANSFUSION AND HEMATOLOGY HOSPITAL
Main Article Content
Abstract
Background: Acute myeloid leukemia (AML) is a rare malignant disease in children, yet it remains a significant clinical concern due to persistent challenges in management, especially in very young patients. Although infant AML was historically defined as occurring in children under 1 year of age, this definition has been expanded to include patients under 2 years of age, based on data demonstrating similarities in biological and clinical features.
Objective: We conducted this study to describe the clinical and biological characteristics as well as to provide a preliminary evaluation of treatment outcomes of infant AML at the Blood Transfusion and Hematology Hospital (BTH).
Subjects and methods: The retrospective case-series study included 29 patients.
Results: At presentation, the most prevalent manifestations were anemia (89.7%), fever (79.3%), hemorrhage (65.5%), splenomegaly (65.5%), and infection (41.4%). Biologically, the AML M7 subtype predominated (44.8%), while the most frequent cytogenetic aberrations were 11q23 rearrangements (31%) and a complex karyotype (31%). The complete remission rate following 7 - 3 induction therapy was 58.6%. The relapse rate was 40.9%. The 5-year overall survival (OS) and event-free survival (EFS) were 48.1% (95% CI: 29.1 - 67.1%) and 40.8% (95% CI: 22.0 - 59.6%), respectively.
Conclusion: These findings suggest that AML in infants requires greater attention, with more specialized treatment strategies and supportive care in order to improve treatment outcomes and prognosis for this particular patient population.
Keywords
acute myeloid leukemia, childhood, infant